The protein interaction network of the inherited central nervous system diseases reveals new gene candidates for molecularly unclassified myelin disorders

2020 ◽  
Vol 8 (4) ◽  
Author(s):  
Luca Paris ◽  
Gianluca Como ◽  
Ilaria Vecchia ◽  
Francesco Pisani ◽  
Giovanni Ferrara

Abstract Mutations in numerous genes cause the inherited disorders of the white matter in the central nervous system. Interestingly, all these mutations ultimately affect myelin, even though the corresponding proteins are involved in dissimilar functions. To address this system-level issue, we assembled the myelin disease network (MDN), in which each node represents a protein (either the mutated protein or one of its interactors), while each edge linking two nodes represents the physical interaction between the two proteins. Compared with control random networks, the MDN contains more pairs of disease proteins, whose members are linked either directly or via one intermediate protein. Then, we surmised that the interactions might not only cluster proteins into functionally homogenous and distinct modules but also link the modules together. This way, even gene mutations arising in functionally distinct modules might propagate their effects to the other modules, thus accounting for a similar pathological outcome. We found, however, that concerning the function the modules are neither homogeneous nor distinct, mostly because many proteins participate in more than one biological process. Rather, our analysis defines a region of the interactome, where different processes intersect. Finally, we propose that many non-disease proteins in the network might be candidates for molecularly unclassified myelin disorders.

Author(s):  
Kohei Shiota

ABSTRACT The organogenesis of the central nervous system (CNS) begins during the third week of development, but its maturation requires a considerably long period of time until after birth. Therefore the developing nervous system is vulnerable to the deleterious effects of environmental factors during the pre- and perinatal periods. In addition, molecular studies have revealed various gene mutations that are responsible for congenital CNS disorders. This chapter provides an overview of the prenatal development of the human brain and spinal cord. How to cite this article Shiota K. Prenatal Development of the Human Central Nervous System, Normal and Abnormal. Donald School J Ultrasound Obstet Gynecol 2015;9(1):61-66.


1993 ◽  
Vol 8 (6) ◽  
pp. 285-291 ◽  
Author(s):  
M Bourin ◽  
A Couetoux du Tertre ◽  
R Payeur

SummaryAs with other drugs it is necessary to look for changes induced by anxiolytics on vital signs, laboratory parameters and adverse events. In return, in a more specific way for anxiolytics, we will look at side effects at the central nervous system level with psychological and physiological battery tests. We will also assess the safety of use of anxiolytics in certain specific conditions, such as overdose or withdrawal and in certain populations such as the elderly, neonates and children. The assessment of safety and side effects, whatever the drug type studied, must come early in the developing process of a drug (phases I, II and III).


Author(s):  
Ryan Koeppen ◽  
Meghan E. Huber ◽  
Dagmar Sternad ◽  
Neville Hogan

Physical interaction with tools is ubiquitous in functional activities of daily living. While tool use is considered a hallmark of human behavior, how humans control such physical interactions is still poorly understood. When humans perform a motor task, it is commonly suggested that the central nervous system coordinates the musculo-skeletal system to minimize muscle effort. In this paper, we tested if this notion holds true for motor tasks that involve physical interaction. Specifically, we investigated whether humans minimize muscle forces to control physical interaction with a circular kinematic constraint. Using a simplified arm model, we derived three predictions for how humans should behave if they were minimizing muscular effort to perform the task. First, we predicted that subjects would exert workless, radial forces on the constraint. Second, we predicted that the muscles would be deactivated when they could not contribute to work. Third, we predicted that when moving very slowly along the constraint, the pattern of muscle activity would not differ between clockwise (CW) and counterclockwise (CCW) motions. To test these predictions, we instructed human subjects to move a robot handle around a virtual, circular constraint at a constant tangential velocity. To reduce the effect of forces that might arise from incomplete compensation of neuro-musculo-skeletal dynamics, the target tangential speed was set to an extremely slow pace (∼1 revolution every 13.3 seconds). Ultimately, the results of human experiment did not support the predictions derived from our model of minimizing muscular effort. While subjects did exert workless forces, they did not deactivate muscles as predicted. Furthermore, muscle activation patterns differed between CW and CCW motions about the constraint. These findings demonstrate that minimizing muscle effort is not a significant factor in human performance of this constrained-motion task. Instead, the central nervous system likely prioritizes reducing other costs, such as computational effort, over muscle effort to control physical interactions.


2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Vera van der Velpen ◽  
Tony Teav ◽  
Héctor Gallart-Ayala ◽  
Florence Mehl ◽  
Ioana Konz ◽  
...  

Abstract Background Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer’s disease (AD) on both the systemic and central nervous system level. To study the extent and significance of these alterations in AD, quantitative metabolomics was applied to plasma and cerebrospinal fluid (CSF) from clinically well-characterized AD patients and cognitively healthy control subjects. The observed metabolic alterations were associated with core pathological processes of AD to investigate their relation with amyloid pathology and tau-related neurodegeneration. Methods In a case-control study of clinical and biomarker-confirmed AD patients (n = 40) and cognitively healthy controls without cerebral AD pathology (n = 34) with paired plasma and CSF samples, we performed metabolic profiling, i.e., untargeted metabolomics and targeted quantification. Targeted quantification focused on identified deregulated pathways highlighted in the untargeted assay, i.e. the TCA cycle, and its anaplerotic pathways, as well as the neuroactive tryptophan and kynurenine pathway. Results Concentrations of several TCA cycle and beta-oxidation intermediates were higher in plasma of AD patients, whilst amino acid concentrations were significantly lower. Similar alterations in these energy metabolism intermediates were observed in CSF, together with higher concentrations of creatinine, which were strongly correlated with blood-brain barrier permeability. Alterations of several amino acids were associated with CSF Amyloidβ1–42. The tryptophan catabolites, kynurenic acid and quinolinic acid, showed significantly higher concentrations in CSF of AD patients, which, together with other tryptophan pathway intermediates, were correlated with either CSF Amyloidβ1–42, or tau and phosphorylated Tau-181. Conclusions This study revealed AD-associated systemic dysregulation of nutrient sensing and oxidation and CNS-specific alterations in the neuroactive tryptophan pathway and (phospho)creatine degradation. The specific association of amino acids and tryptophan catabolites with AD CSF biomarkers suggests a close relationship with core AD pathology. Our findings warrant validation in independent, larger cohort studies as well as further investigation of factors such as gender and APOE genotype, as well as of other groups, such as preclinical AD, to identify metabolic alterations as potential intervention targets.


2010 ◽  
Vol 38 (2) ◽  
pp. 695-701 ◽  
Author(s):  
Grzegorz Węgrzyn ◽  
Joanna Jakóbkiewicz-Banecka ◽  
Magdalena Gabig-Cimińska ◽  
Ewa Piotrowska ◽  
Magdalena Narajczyk ◽  
...  

Genistein [4′,5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one] is a natural isoflavone occurring in many plants known to possess various biological activities, ranging from phyto-oestrogenic to antioxidative actions. Recent studies indicated that this isoflavone can also be considered as a drug for as yet untreatable genetic diseases. In the present review, we discuss a plausible use of genistein in treatment of two genetic disorders: CF (cystic fibrosis) and MPS (mucopolysaccharidosis). Although various biological actions of genistein are employed in these two cases, in vitro studies, tests on animal models and pilot clinical trials suggest that this plant-derived compound might be a real hope for patients suffering from severe inherited disorders with relatively complicated pathomechanisms, including those affecting the central nervous system.


Sign in / Sign up

Export Citation Format

Share Document